Signal · Supply Chain & Logistics
Maharashtra FDA cancels Cipla's Pune warehouse licences over Reactin Plus packaging claims
What the source reported
Source-reportedMaharashtra's Food and Drug Administration has cancelled Cipla Pharma's distribution licenses due to serious violations. The FDA discovered irregularities with Reactin Plus Tablets, including misbranding and unsafe storage practices. Following inspections, it was revealed that expired medicines were stored incorrectly without proper documentation. The licensing authority’s decision was based on findings from earlier proceedings and legal directions.
- Publication
- The Economic Times - Industry · Trade Publication
- Published
- 2nd October 2026
- Original report
- economictimes.indiatimes.com
ProcIntel stores what the source published in its feed — a headline, a summary and a link. It does not store or reproduce the full article.
What ProcIntel recorded
ProcIntel-derived- Category
- Supply Chain & Logistics
- Geography
- India
- Organisations
- None identified
- Collected
- 2nd October 2026 · 14:20
Initial assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
Initial Significance Low (13.0/100). Strongest contributor: Procurement Impact (6.0/30 points). Limiting factor: Geographic Breadth (0.0/10 points). Initial Confidence Low (25.5/100, data sufficiency: Insufficient). Strongest contributor: Source Authority (20.0/40 points). Limiting factor: Specificity (0.0/20 points).
- Strongest contributor
- Procurement Impact
- Limiting factor
- Geographic Breadth